Investigation of responses to erythropoiesis stimulating agents (ESA) for the initial treatment of renal anemia in patients with chronic kidney disease

Investigation of responses to erythropoiesis stimulating agents (ESA) for the initial treatment of renal anemia in patients with chronic kidney disease - Investigation of responses to erythropoiesis stimulating agents (ESA) for the initial treatment of renal anemia in patients with chronic kidney disease

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009472

Enrollment

Registered

2012-12-04

Start date

2012-12-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal anemia in chronic kidney disease

Interventions

CERA Group: Epoetin beta pegol is subcutaneously administered once every two weeks. rHuEPO Group: rHuEPO is subcutaneously administered once every two weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients with no prior treatment with ESA (2)Patients 20 years old or older at time of study initiation (3)Patients with a hemoglobin (Hb) level of >= 8 g/dL and < 11 g/dL (4)Patients with eGFR of < 60 mL/min/1.73m2 (5)Patients who give written informed consent

Exclusion criteria

Exclusion criteria: (1)Patients on hemodialysis or peritoneal dialysis (2)Patients who underwent renal transplant (3)Patients with malignancy or hematological diseases (such as MDS) (4)Patients with severe complications, such as severe infections (5)Patients who take iron therapy (6)Patients who are judged to be ineligible by an attending doctor

Design outcomes

Primary

Measure	Time frame
(1)Comparison of changes in hepcidin concentrations between patients treated with rHuEPO or those treated with epoetin beta pegol (2)Identification of factors affecting the treatment response to rHuEPO or epoetin beta pegol	—

Secondary

Measure	Time frame
(1)Effects of rHuEPO and epoetin beta pegol on iron metabolism (2)Changes in dosage of epoetin beta pegol and Hb level	—

Countries

Japan

Contacts

Public ContactKoji Mitsuiki

Fukuoka Red Cross Hospital Division of Nephrology

koji@fukuoka-med.jrc.or.jp092-551-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026